文献速递甲状腺疾病

命名变化对美国甲状腺乳头状癌发病率趋势的影响(2000-2017)

Influence of Nomenclature Changes on Trends in Papillary Thyroid Cancer Incidence in the United States, 2000 to 2017.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该研究基于美国SEER-18癌症登记数据(2000-2017),描述甲状腺乳头状癌(PTC)及NIFTP的发病率趋势。PTC发病率在2015-2017年首次下降(APC=-4.6%/年,95%CI -7.6%至-1.4%),滤泡变异型PTC(FVPTC)急剧下降(APC=-21.1%/年,95%CI -26.5%至-15.2%),NIFTP的增加仅解释FVPTC下降的10%。

要点

  • 2015-2017年PTC总体发病率下降,所有肿瘤大小均下降。
  • FVPTC发病率在2015-2017年急剧下降,所有肿瘤大小均下降。
  • NIFTP命名变化仅解释FVPTC下降的10%,不能完全解释趋势。

核心结论

  • PTC发病率趋势的原因是多因素的。
  • FVPTC发病率在2015-2017年的急剧下降与临床实践和诊断编码变化(包括将非浸润性包裹性FVPTC重新分类为NIFTP)同时发生。
  • 观察到的NIFTP增加仅占FVPTC下降的10%。

研究设计与样本

  • 描述性研究,使用美国SEER-18癌症登记数据(2000-2017)。
  • 纳入2000-2017年诊断为PTC或2016-2017年诊断为NIFTP的个体。

主要发现

  • 2000-2015年PTC发病率平均每年增加7.3%(95%CI 6.9%至7.8%),2000-2009年APC为7.3%(95%CI 6.9%至7.8%),2009-2012年APC为3.7%(95%CI 0.2%至7.3%),2012-2015年趋于稳定(APC=1.4%/年,95%CI -1.8%至4.7%),2015-2017年下降(APC=-4.6%/年,95%CI -7.6%至-1.4%)。
  • 2015-2017年FVPTC总体发病率急剧下降(APC=-21.1%/年;95%CI -26.5%至-15.2%),所有肿瘤大小均下降。
  • encapsulated papillary carcinoma(经典型PTC亚型)和NIFTP的观察增加各占FVPTC下降的10%。
  • 经典型PTC发病率持续增加(2000-2009年APC=8.7%/年,95%CI 8.1%至9.4%;2009-2017年APC=1.0%/年,95%CI 0.4%至1.5%),总体及除小于1cm外的所有大小。
  • 其他PTC变异型合计发病率增加(2000-2017年APC=5.9%/年,95%CI 4.0%至7.9%)。

临床怎么用

  • 临床解读PTC发病率下降时需考虑NIFTP命名和诊断编码变化的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: US papillary thyroid carcinoma (PTC) incidence recently declined for the first time in decades, for reasons that remain unclear. OBJECTIVE: This work aims to evaluate PTC incidence trends, including by histologic subtype and size, and noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). DESIGN: This descriptive study uses US Surveillance, Epidemiology, and End Results-18 cancer registry data (2000-2017). PATIENTS: Participants included individuals diagnosed with PTC (2000-2017) or NIFTP (2016-2017). RESULTS: During 2000 to 2015, PTC incidence increased an average 7.3% per year, (95% CI, 6.9% to 7.8%) during 2000 to 2009, and 3.7% per year (95% CI, 0.2% to 7.3%) during 2009 to 2012, before stabilizing in 2012 to 2015 (annual percentage change [APC] = 1.4% per year, 95% CI, -1.8% to 4.7%) and declining in 2015 to 2017 (APC = -4.6% per year, 95% CI, -7.6% to -1.4%). The recent declines were observed for all sizes of PTC at diagnosis. Incidence of follicular variant of PTC (FVPTC) sharply declined in 2015 to 2017, overall (APC = -21.1% per year; 95% CI, -26.5% to -15.2%) and for all tumor sizes. Observed increases in encapsulated papillary carcinoma (classical PTC subtype) and NIFTP each accounted for 10% of the decline in FVPTC. Classical PTC incidence continuously increased (2000-2009, APC = 8.7% per year, 95% CI, 8.1% to 9.4%; 2009-2017, APC = 1.0% per year, 95% CI, 0.4% to 1.5%), overall and for all sizes except smaller than 1 cm, as did incidence of other PTC variants combined (2000-2017, APC = 5.9% per year, 95% CI, 4.0% to 7.9%). CONCLUSION: The reasons underlying PTC incidence trends were multifactorial. Sharp declines in FVPTC incidence during 2015 to 2017 coincided with clinical practice and diagnostic coding changes, including reclassification of noninvasive encapsulated FVPTC from a malignant to in situ neoplasm (NIFTP). Observed increases in NIFTP accounted for 10% of the decline in FVPTC.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kitahara CM, Sosa JA, Shiels MS, et al. Influence of Nomenclature Changes on Trends in Papillary Thyroid Cancer Incidence in the United States, 2000 to 2017. J Clin Endocrinol Metab. 2020. PMID: 32984898. doi:10.1210/clinem/dgaa690

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。